Huntsman Corporation has attracted coverage from fourteen sell-side analysts over the past year, resulting in an average recommendation of “Reduce.” Four firms have urged a sell stance, eight have maintained a hold view, and two have offered buy ratings. Recent updates include Goldman Sachs lowering its outlook to “sell” with a revised target, Citigroup shifting to “neutral” after lifting its price projection, and JPMorgan trimming its price objective but retaining an overweight rating. This diversity of views underscores mixed sentiment among major brokerages regarding Huntsman’s near-term performance.

In its latest quarter, Huntsman reported adjusted losses per share of $0.03, beating the consensus estimate of a $0.13 loss by $0.10. Revenue totaled $1.46 billion, narrowly surpassing analyst projections, but marked a 5.2% year-over-year decline. The firm recorded a negative net margin of 5.7% and a return on equity of negative 3.3%, reflecting persistent margin pressures in its core chemical operations. Equities analysts now forecast full-year earnings per share of $0.32, indicating modest profitability expectations compared to prior years.

Huntsman recently declared a quarterly dividend of $0.0875 per share, translating to an annualized yield of approximately 3.5% based on its declared payout. The ex-dividend date was mid-December, with payment at year-end. Meanwhile, institutional ownership remains robust at over 84% of shares outstanding. Notable activity includes new stakes taken by several boutique advisory firms during the third quarter, while long-only managers modestly trimmed positions, suggesting selective accumulation ahead of year-end portfolio rebalancing.